GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• GSK has a consensus “Hold” rating from 10 brokerages: six holds, two sells, one buy and one strong buy. The average 12-month price target is $53.00, compared with the reported share price of $50.80.
• GSK’s latest quarterly results exceeded expectations, with EPS of $1.36 versus the $1.27 consensus and revenue of $11.14 billion. Revenue increased 5.3% year over year, while the company guided to fiscal 2026 EPS of $4.90–$5.00.
• The company increased its quarterly dividend to $0.4515 per share, implying an annualized dividend of $1.81 and a 3.6% yield. Institutional investors own 15.74% of GSK’s stock.

GSK PLC Sponsored ADR (NYSE:GSK - Get Free Report) has received a consensus recommendation of "Hold" from the ten brokerages that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $53.00.

Several research analysts recently issued reports on the company. Morgan Stanley reissued an "underweight" rating on shares of GSK in a research note on Tuesday, August 25th. Weiss Ratings lowered GSK from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Wednesday, July 29th. Wall Street Zen downgraded GSK from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of GSK in a report on Thursday, July 30th. Finally, Royal Bank Of Canada reissued an "outperform" rating on shares of GSK in a research report on Tuesday, June 9th.

Hedge Funds Weigh In On GSK

A number of large investors have recently bought and sold shares of GSK. Elyxium Wealth LLC purchased a new stake in GSK during the fourth quarter worth $30,000. Triumph Capital Management bought a new position in shares of GSK in the 3rd quarter worth $40,000. Trust Co. of Vermont bought a new position in shares of GSK in the 2nd quarter worth $54,000. Coston McIsaac & Partners lifted its stake in shares of GSK by 17.3% during the 4th quarter. Coston McIsaac & Partners now owns 1,395 shares of the pharmaceutical company's stock worth $68,000 after purchasing an additional 206 shares during the last quarter. Finally, Philadelphia Investment Partners LLC purchased a new stake in shares of GSK during the 2nd quarter worth $70,000. Institutional investors own 15.74% of the company's stock.

GSK Trading Down 0.0%

Shares of GSK opened at $50.80 on Monday. GSK has a 1-year low of $38.63 and a 1-year high of $61.69. The company has a 50-day moving average of $51.82 and a 200 day moving average of $53.45. The firm has a market capitalization of $102.75 billion, a price-to-earnings ratio of 15.88, a PEG ratio of 2.93 and a beta of 0.36. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.82 and a quick ratio of 0.52.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.09. The company had revenue of $11.14 billion during the quarter, compared to analysts' expectations of $11.02 billion. GSK had a net margin of 14.56% and a return on equity of 43.23%. The firm's quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.47 EPS. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. On average, research analysts expect that GSK will post 4.8 EPS for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 8th. Stockholders of record on Friday, August 14th will be paid a dividend of $0.4515 per share. This is a boost from GSK's previous quarterly dividend of $0.44. This represents a $1.81 dividend on an annualized basis and a dividend yield of 3.6%. The ex-dividend date is Friday, August 14th. GSK's payout ratio is 55.63%.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK's core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source